Apalutamide Confirms Overall Survival Benefit at 44-Months in Metastatic Castration-Sensitive Prostate Cancer – The TITAN Study – Neeraj Agarwal
In 2019 the first interim analysis of the phase III TITAN trial was reported which led to the approval of apalutamide for metastatic castration-sensitive prostate cancer (mCSPC). In this conversation with Alicia Morgans, MD, MPH, Neeraj Agarwal, MD highlights the final overall survival analysis after a median follow-up of 44 months (nearly 4-years) and the recent final survival analysis Journal…
